Diagnosing the decline in pharmaceutical R&D efficiency
Jack W. Scannell, Alex Blanckley, Helen Boldon et al. · Nature Reviews Drug Discovery · 2012
Cited by 1,969 works. doi:10.1038/nrd3681
Authors
References
- Collective dynamics of ‘small-world’ networks
- Nucleotide sequence of bacteriophage G4 DNA
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
- Nucleotide sequence of bacteriophage φX174 DNA
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
- Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000
- Can the pharmaceutical industry reduce attrition rates?